European position statement on lung cancer screening

Matthijs Oudkerk, Anand Devaraj, Rozemarijn Vliegenthart, Thomas Henzler, Helmut Prosch, Claus P. Heussel, Gorka Bastarrika, Nicola Sverzellati, Mario Mascalchi, Stefan Delorme, David R. Baldwin, Matthew E. Callister, Nikolaus Becker, Marjolein A. Heuvelmans, Witold Rzyman, Maurizio V. Infante, Ugo Pastorino, Jesper H. Pedersen, Eugenio Paci, Stephen W. DuffyHarry de Koning, John K. Field

Research output: Contribution to journalReview article

Abstract

Lung cancer screening with low-dose CT can save lives. This European Union (EU) position statement presents the available evidence and the major issues that need to be addressed to ensure the successful implementation of low-dose CT lung cancer screening in Europe. This statement identified specific actions required by the European lung cancer screening community to adopt before the implementation of low-dose CT lung cancer screening. This position statement recommends the following actions: a risk stratification approach should be used for future lung cancer low-dose CT programmes; that individuals who enter screening programmes should be provided with information on the benefits and harms of screening, and smoking cessation should be offered to all current smokers; that management of detected solid nodules should use semi-automatically measured volume and volume-doubling time; that national quality assurance boards should be set up to oversee technical standards; that a lung nodule management pathway should be established and incorporated into clinical practice with a tailored screening approach; that non-calcified baseline lung nodules greater than 300 mm3, and new lung nodules greater than 200 mm3, should be managed in multidisciplinary teams according to this EU position statement recommendations to ensure that patients receive the most appropriate treatment; and planning for implementation of low-dose CT screening should start throughout Europe as soon as possible. European countries need to set a timeline for implementing lung cancer screening.

Original languageEnglish
Pages (from-to)e754-e766
JournalThe Lancet Oncology
Volume18
Issue number12
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Early Detection of Cancer
Lung Neoplasms
European Union
Lung
Smoking Cessation

ASJC Scopus subject areas

  • Oncology

Cite this

Oudkerk, M., Devaraj, A., Vliegenthart, R., Henzler, T., Prosch, H., Heussel, C. P., ... Field, J. K. (2017). European position statement on lung cancer screening. The Lancet Oncology, 18(12), e754-e766. https://doi.org/10.1016/S1470-2045(17)30861-6

European position statement on lung cancer screening. / Oudkerk, Matthijs; Devaraj, Anand; Vliegenthart, Rozemarijn; Henzler, Thomas; Prosch, Helmut; Heussel, Claus P.; Bastarrika, Gorka; Sverzellati, Nicola; Mascalchi, Mario; Delorme, Stefan; Baldwin, David R.; Callister, Matthew E.; Becker, Nikolaus; Heuvelmans, Marjolein A.; Rzyman, Witold; Infante, Maurizio V.; Pastorino, Ugo; Pedersen, Jesper H.; Paci, Eugenio; Duffy, Stephen W.; de Koning, Harry; Field, John K.

In: The Lancet Oncology, Vol. 18, No. 12, 01.12.2017, p. e754-e766.

Research output: Contribution to journalReview article

Oudkerk, M, Devaraj, A, Vliegenthart, R, Henzler, T, Prosch, H, Heussel, CP, Bastarrika, G, Sverzellati, N, Mascalchi, M, Delorme, S, Baldwin, DR, Callister, ME, Becker, N, Heuvelmans, MA, Rzyman, W, Infante, MV, Pastorino, U, Pedersen, JH, Paci, E, Duffy, SW, de Koning, H & Field, JK 2017, 'European position statement on lung cancer screening', The Lancet Oncology, vol. 18, no. 12, pp. e754-e766. https://doi.org/10.1016/S1470-2045(17)30861-6
Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP et al. European position statement on lung cancer screening. The Lancet Oncology. 2017 Dec 1;18(12):e754-e766. https://doi.org/10.1016/S1470-2045(17)30861-6
Oudkerk, Matthijs ; Devaraj, Anand ; Vliegenthart, Rozemarijn ; Henzler, Thomas ; Prosch, Helmut ; Heussel, Claus P. ; Bastarrika, Gorka ; Sverzellati, Nicola ; Mascalchi, Mario ; Delorme, Stefan ; Baldwin, David R. ; Callister, Matthew E. ; Becker, Nikolaus ; Heuvelmans, Marjolein A. ; Rzyman, Witold ; Infante, Maurizio V. ; Pastorino, Ugo ; Pedersen, Jesper H. ; Paci, Eugenio ; Duffy, Stephen W. ; de Koning, Harry ; Field, John K. / European position statement on lung cancer screening. In: The Lancet Oncology. 2017 ; Vol. 18, No. 12. pp. e754-e766.
@article{e98bc20fa54a414c814bda50d2c30407,
title = "European position statement on lung cancer screening",
abstract = "Lung cancer screening with low-dose CT can save lives. This European Union (EU) position statement presents the available evidence and the major issues that need to be addressed to ensure the successful implementation of low-dose CT lung cancer screening in Europe. This statement identified specific actions required by the European lung cancer screening community to adopt before the implementation of low-dose CT lung cancer screening. This position statement recommends the following actions: a risk stratification approach should be used for future lung cancer low-dose CT programmes; that individuals who enter screening programmes should be provided with information on the benefits and harms of screening, and smoking cessation should be offered to all current smokers; that management of detected solid nodules should use semi-automatically measured volume and volume-doubling time; that national quality assurance boards should be set up to oversee technical standards; that a lung nodule management pathway should be established and incorporated into clinical practice with a tailored screening approach; that non-calcified baseline lung nodules greater than 300 mm3, and new lung nodules greater than 200 mm3, should be managed in multidisciplinary teams according to this EU position statement recommendations to ensure that patients receive the most appropriate treatment; and planning for implementation of low-dose CT screening should start throughout Europe as soon as possible. European countries need to set a timeline for implementing lung cancer screening.",
author = "Matthijs Oudkerk and Anand Devaraj and Rozemarijn Vliegenthart and Thomas Henzler and Helmut Prosch and Heussel, {Claus P.} and Gorka Bastarrika and Nicola Sverzellati and Mario Mascalchi and Stefan Delorme and Baldwin, {David R.} and Callister, {Matthew E.} and Nikolaus Becker and Heuvelmans, {Marjolein A.} and Witold Rzyman and Infante, {Maurizio V.} and Ugo Pastorino and Pedersen, {Jesper H.} and Eugenio Paci and Duffy, {Stephen W.} and {de Koning}, Harry and Field, {John K.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/S1470-2045(17)30861-6",
language = "English",
volume = "18",
pages = "e754--e766",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "12",

}

TY - JOUR

T1 - European position statement on lung cancer screening

AU - Oudkerk, Matthijs

AU - Devaraj, Anand

AU - Vliegenthart, Rozemarijn

AU - Henzler, Thomas

AU - Prosch, Helmut

AU - Heussel, Claus P.

AU - Bastarrika, Gorka

AU - Sverzellati, Nicola

AU - Mascalchi, Mario

AU - Delorme, Stefan

AU - Baldwin, David R.

AU - Callister, Matthew E.

AU - Becker, Nikolaus

AU - Heuvelmans, Marjolein A.

AU - Rzyman, Witold

AU - Infante, Maurizio V.

AU - Pastorino, Ugo

AU - Pedersen, Jesper H.

AU - Paci, Eugenio

AU - Duffy, Stephen W.

AU - de Koning, Harry

AU - Field, John K.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Lung cancer screening with low-dose CT can save lives. This European Union (EU) position statement presents the available evidence and the major issues that need to be addressed to ensure the successful implementation of low-dose CT lung cancer screening in Europe. This statement identified specific actions required by the European lung cancer screening community to adopt before the implementation of low-dose CT lung cancer screening. This position statement recommends the following actions: a risk stratification approach should be used for future lung cancer low-dose CT programmes; that individuals who enter screening programmes should be provided with information on the benefits and harms of screening, and smoking cessation should be offered to all current smokers; that management of detected solid nodules should use semi-automatically measured volume and volume-doubling time; that national quality assurance boards should be set up to oversee technical standards; that a lung nodule management pathway should be established and incorporated into clinical practice with a tailored screening approach; that non-calcified baseline lung nodules greater than 300 mm3, and new lung nodules greater than 200 mm3, should be managed in multidisciplinary teams according to this EU position statement recommendations to ensure that patients receive the most appropriate treatment; and planning for implementation of low-dose CT screening should start throughout Europe as soon as possible. European countries need to set a timeline for implementing lung cancer screening.

AB - Lung cancer screening with low-dose CT can save lives. This European Union (EU) position statement presents the available evidence and the major issues that need to be addressed to ensure the successful implementation of low-dose CT lung cancer screening in Europe. This statement identified specific actions required by the European lung cancer screening community to adopt before the implementation of low-dose CT lung cancer screening. This position statement recommends the following actions: a risk stratification approach should be used for future lung cancer low-dose CT programmes; that individuals who enter screening programmes should be provided with information on the benefits and harms of screening, and smoking cessation should be offered to all current smokers; that management of detected solid nodules should use semi-automatically measured volume and volume-doubling time; that national quality assurance boards should be set up to oversee technical standards; that a lung nodule management pathway should be established and incorporated into clinical practice with a tailored screening approach; that non-calcified baseline lung nodules greater than 300 mm3, and new lung nodules greater than 200 mm3, should be managed in multidisciplinary teams according to this EU position statement recommendations to ensure that patients receive the most appropriate treatment; and planning for implementation of low-dose CT screening should start throughout Europe as soon as possible. European countries need to set a timeline for implementing lung cancer screening.

UR - http://www.scopus.com/inward/record.url?scp=85035357095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035357095&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(17)30861-6

DO - 10.1016/S1470-2045(17)30861-6

M3 - Review article

C2 - 29208441

AN - SCOPUS:85035357095

VL - 18

SP - e754-e766

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 12

ER -